Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$9.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/14/22

Today's Change+0.42(4.88%)
Bid (Size)$8.30 (2)
Ask (Size)$9.03 (2)
Day Low / High$8.35 - 9.05
Volume331.5 K

View Biotechnology IndustryPeer Comparison as of 01/14/2022


Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $9.03
Change: +0.42 (4.88%)
Volume: 331.5 K
4:00PM ET 1/14/2022

Mersana Therapeutics Inc ( NASDAQ )

Price: $6.28
Change: +0.26 (4.32%)
Volume: 831.7 K
4:00PM ET 1/14/2022

Viridian Therapeutics Inc ( NASDAQ )

Price: $20.00
Change: +0.99 (5.21%)
Volume: 103.8 K
4:00PM ET 1/14/2022

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $2.42
Change: +0.11 (4.76%)
Volume: 1.6 M
4:00PM ET 1/14/2022

22nd Century Group Inc ( NASDAQ )

Price: $2.47
Change: -0.04 (1.59%)
Volume: 1.7 M
4:00PM ET 1/14/2022

Read more news Recent News

Rhythm Pharmaceuticals Doses First Patients in Clinical Trials of Setmelanotide for Treating Genetic Obesity
10:24AM ET 1/13/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Thursday the first patients have been dosed with setmelanotide in a phase 2 trial to treat genetic obesity and in a...

Wells Fargo Starts Rhythm Pharmaceuticals at Overweight With $30 Price Target
8:19AM ET 12/08/2021 MT Newswires

Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $14 to $50, according to analysts polled by Capital IQ....

Rhythm Pharmaceuticals Agrees to License Development, Commercialization of Obesity Drug to China's RareStone
9:47AM ET 12/06/2021 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Monday it agreed to grant RareStone an exclusive license to develop and commercialize Imcivree as a potential treatment...

Morgan Stanley Downgrades Rhythm Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $15 From $50
9:32AM ET 11/19/2021 MT Newswires

Rhythm Pharmaceuticals (RYTM) has an average outperform rating and a price target range of $14 to $50, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionRhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. View company web site for more details
Address222 Berkeley Street
Boston, Massachusetts 02116
Number of Employees54
Recent SEC Filing12/10/2021SC 13G/A
Chairman, President & Chief Executive OfficerDavid P. Meeker
Chief Financial Officer & TreasurerHunter C. Smith
Head of ResearchAlastair Garfield
Vice President-Medical AffairsBrieana Buckley

Company Highlights

Price Open$8.49
Previous Close$8.61
52 Week Range$8.33 - 43.26
Market Capitalization$453.9 M
Shares Outstanding50.3 M
SectorHealth Technology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.29
Beta vs. S&P 500N/A
Net Profit Margin-4,610.55%
Return on Equity-20.19%

Analyst Ratings as of 12/09/2021

Consensus RecommendationConsensus Icon
Powered by Factset